Views & Analysis What is pharmaceutical market access? Findings from a comprehensive survey on the topic of market access.
Views & Analysis UK life sciences: the impact of a cycle of affordability and... The changing landscape for drug pricing and some pointers for the UK life sciences sector.
News NHS funding for five MS drugs under threat NICE calls for further discounts on beta-interferons and Copaxone
Views & Analysis The honest broker in market access Eric Low shares his views on why hurdles remain to new drug access.
News Pfizer's Ibrance available across UK after thumbs up in Scot... Around 800 women have received the drug for free.
News NICE recommends Eisai's kidney cancer combination NICE has recommended Eisai’s Kisplyx (lenvatinib) in combination with Novartis’ Afinitor (everolimus) in kidney cancer after the company further dropped its price.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.